Cargando…
An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients
OBJECTIVES: The present study was performed with the aim of analyzing the biological disease-modifying antirheumatic drug (bDMARD)-free (Bio-free) condition of adalimumab (ADA)-treated rheumatoid arthritis (RA) patients in a real-world setting. METHODS: ADA was used in the treatment of 130 (male, n=...
Autores principales: | Ito, Satoshi, Kobayashi, Daisuke, Hasegawa, Eriko, Takai, Chinatsu, Nemoto, Tetsuya, Lee, Hyunho, Abe, Asami, Otani, Hiroshi, Ishikawa, Hajime, Murasawa, Akira, Narita, Ichiei, Nakazono, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421140/ https://www.ncbi.nlm.nih.gov/pubmed/30210123 http://dx.doi.org/10.2169/internalmedicine.1332-18 |
Ejemplares similares
-
The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023) -
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2020) -
Erratum for
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center
por: Takai, Chinatsu, et al.
Publicado: (2021) -
Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020) -
Erratum for
Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)